FT-1518 ,exhibits antitumor activity, is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor.

FT-1518 cuases potent inhibition of the mTOR pathway biomarkers (mTORC 1 & 2 biomarkers [pAkt(S473) and pS6(S240/244) or p70 S6K), no inhibition of PI3K biomarker [pAkt(T308)] in cells.FT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity. FT-1518 displays significant growth inhibitory activity against a large panel of hematologic and solid tumor cell lines with most activities falling into low nanomolar range.

FT-1518 exhibits dose-dependent and higher tumor growth inhibition (TGI) in multiple solid tumor xenografts.

1313026-58-2

C20H26N8O

394.47

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years